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Abstract
Evidence supporting aspirin and resistant starch (RS) for colorectal cancer prevention comes from
epidemiological and laboratory studies (aspirin and RS) and randomized controlled clinical trials
(aspirin). Familial adenomatous polyposis (FAP) strikes young people and, untreated, confers
virtually a 100% risk of colorectal cancer and early death. We conducted an international,
multicenter, randomized, placebo-controlled trial of aspirin (600 mg/day) and/or RS (30 g/day) for
from 1 to 12 years to prevent disease progression in FAP patients from 10 to 21 years of age. In a
2 × 2 factorial design, patients were randomly assigned to the following four study arms: aspirin
plus RS placebo; RS plus aspirin placebo; aspirin plus RS; RS placebo plus aspirin placebo; they
were followed with standard annual clinical examinations including endoscopy. The primary
endpoint was polyp number in the rectum and sigmoid colon (at the end of intervention), and the
major secondary endpoint was size of the largest polyp. A total of 206 randomized FAP patients
commenced intervention, of whom 133 had at least 1 follow-up endoscopy and so were included
in the primary analysis. Neither intervention significantly reduced polyp count in the rectum and
sigmoid colon: aspirin relative risk (RR) = 0.77 (95% confidence interval [CI], 0.54–1.10; versus
non-aspirin arms); RS RR = 1.05 (95% CI, 0.73–1.49; versus non-RS arms). There was a trend
toward a smaller size of largest polyp in patients treated with aspirin versus non-aspirin—mean
3.8 mm versus 5.5 mm for patients treated one or more years (adjusted P = 0.09) and mean 3.0
mm versus 6.0 mm for patients treated more than one year (P = 0.02); there were weaker such
trends with RS versus non-RS. Exploratory translational endpoints included crypt length (which
was significantly shorter in normal-appearing mucosa in the RS group over time) and laboratory
measures of proliferation (including Ki67). This clinical trial is the largest one ever conducted in
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the setting of FAP and found a trend of reduced polyp load (number and size) with 600 mg of
aspirin daily. RS had no clinical effect on adenomas.
Introduction
Somatic mutations in the adenomatous polyposis coli (APC) gene are found in most
colorectal cancers (CRCs) and many CR adenomas. Germline APC defects underlie the
disease familial adenomatous polyposis (FAP), which is characterized by the development
of thousands of CR polyps beginning typically during puberty. Therefore, FAP patients
represent a powerful model for CRC chemoprevention studies.
Consistent evidence of a protective effect of aspirin against CR neoplasia in 27 cohort or
case-control studies (1, 2) contrasts with four randomized trials which found only marginal
evidence in favour of this benefit (3-6). In a study of 1121 patients with a history of
adenoma formation, Baron et al. (4) found that aspirin at 81 mg per day had a small
protective effect (adenoma risk ratio [RR] = 0.81; 95% confidence interval [CI], 0.69–0.96),
whereas aspirin at 325 mg daily did not (RR = 0.96; 95% CI, 0.81–1.13); the effect of the
lower dose was greater on more advanced lesions (RR = 0.59; 95% CI, 0.38–0.92). A
randomized placebo-controlled trial of aspirin (325 mg) by Sandler et al. (3) in 635 patients
with a previous colorectal cancer found that adenomas developed in 17% of the aspirin
group versus in 27% of the placebo group after 1 year (P = 0.004). Benamouzig et al. (5)
reported that lysine acetylsalicylate treatment resulted in an adenoma RR of 0.73 (95% CI,
0.52–1.04), with a greater effect of 300 mg versus 160 mg of lysine acetylsalicylate and a
significantly reduced risk of advanced lesions (P = 0.01). Most recently, Logan et al. (6)
found that aspirin (300 mg/day) reduced adenoma risk (versus placebo; RR = 0.79; 95% CI,
0.63–0.99) in 939 people who had had an adenoma removed, again with evidence of a
greater impact on advanced lesions.
Nine epidemiological studies have investigated the relationship between starch intake and
CR neoplasms, with higher starch intakes providing neoplasm reductions in the range of
25%–50% (7). Cassidy et al. reported a significant negative correlation between population
starch intakes and colon-cancer incidence (8). Resistant starch (RS) is the sum of starch and
the products of starch digestion not absorbed in the small intestine of healthy individuals (9);
it undergoes colonic fermentation to short-chain fatty acids including butyrate (10). RS
supplementation can improve a number of potential biomarkers of CRC risk including faecal
concentrations of total and secondary bile acids, which it lowers (11, 12). The RS product
butyrate reduces colonic neoplasia in azoxymethane-treated rats (13), and concentrations of
physiological butyrate suppress the in-vitro growth of CRC cell lines and induce G1 cell-
cycle arrest, terminal differentiation, and apoptosis (14-17), probably reflecting its role as an
inhibitor of histone deacetylase. Butyrate and non-steroidal anti-inflammatory drugs
(NSAIDs) differ radically in the transcriptome and proteome modifications they produce in
tumor cells (17, 18).
The first trial conducted within the Colorectal Adenoma/Carcinoma Prevention Programme
(CAPP), the present study (CAPP1) was aimed to test aspirin and RS for preventing
adenoma development in adolescents with FAP and for effects on mucosal crypt dimensions
and cell proliferation, which are potential biomarkers of CRC chemoprevention.
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Materials and Methods
Patient eligibility
Polyposis registry clinicians recruited young male and female patients who met the
following major eligibility criteria: An age of ≥ 10 and ≤ 21 years old and confirmed or a
high likelihood of the presence of FAP. FAP status was determined by molecularly
confirmed carriage of the FAP-associated APC mutation or by the determination of having a
high probability of carrying the mutation on the basis of linked DNA markers or the
presence of multiple colonic polyps, and/or multiple areas of congenital hypertrophy of
retinal pigment epithelium in the context of a known FAP family history. Restricting
eligibility to members of families manifesting classical FAP helped ensure homogeneity of
disease in our study population. Current NSAID therapy, known aspirin sensitivity, major
intercurrent illness, and pregnancy were grounds for exclusion. Advanced FAP was not a
reason for exclusion unless surgery was planned within the next 12 months. The eligibility
cut-off at 21 years old was based on concerns that continuation beyond this age might risk
delaying preventive surgery. All patients were required to provide written consent to
participate in the trial; written consent was required from the parents of patients under age
16 years. They were advised strongly to avoid all products containing aspirin or other
NSAIDs and to use paracetamol for pain relief.
Trial design
We conducted an international, multicenter, double-blind, randomized trial with four arms:
aspirin (600 mg as 2 tablets/d) plus matched placebo, RS (30 g as 2 sachets/d in a 1:1 blend
of potato starch and high amylose maize starch [Hylon VII]) plus matched placebo, aspirin
plus RS, and placebo plus placebo; this trial employed a 2 × 2 factorial design. All polyposis
registries and clinics in Europe were invited to participate in the CAPP1 Study. Our accrual
goal was 208 patients, 52 in each of the four intervention arms.
Randomization was performed centrally at Leeds University via a blocked randomization
scheme with a block size of 16 so that each set of 16 recruits contained 4 persons within
each of the 2-×-2 trial arms. The blocked randomization was stratified at the level of
geographical regions recruiting sufficient numbers of participants in order to avoid
confounding of trial results due to geographical differences (e.g., regional diet); the regional
strata were as follows: United Kingdom, Scandinavia, Northern Europe and southern
Europe. Last, if siblings were enrolled, we assigned each member of such family groups the
same combination to remove the potential for package mix-ups within the family. The
duration of intervention was from 1 to a potential maximum of 12 years, with a scheduled
annual clinical examination including endoscopy. Patients were advised of their option to
leave intervention after each annual examination but were invited to remain on intervention
(up to and including age 21 years).
The primary trial endpoint was the proportion of patients with an increased polyp count in
the rectum and sigmoid colon after intervention. A major secondary endpoint was size of the
largest polyp, which was chosen as another quantifiable and objective measure of disease
severity. Given the multiple, international centers participating in this trial, it was not
feasible to influence the clinical decision on whether the largest polyp was removed or left
in situ nor to tattoo any polyps for review at a later examination. We also assessed crypt
dimensions. Secondary laboratory endpoints included proliferative-state assessments of 1)
crypt-cell proliferation (CCP) measured by direct counting of mitoses and of 2) indices of
proliferation measured using antibodies against proliferating-cell nuclear antigen (PCNA)
and Ki67.
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The RS dose was based on the maximum easily tolerated doses and doses used previously in
short-term intervention studies with CRC biomarkers as endpoints (19, 20). Aspirin and its
matched placebo were supplied by Bayer (Leverkusen, Germany); the matched placebo was
a lactose tablet (packaged at the pharmacy of Freeman Hospital in Newcastle). RS and its
matched placebo were supplied by the National Starch and Chemical Company
(Bridgewater, New Jersey); the matched placebo was 30 g/d of digestible corn (maize)
starch. Children under 45 kg or under 12 years of age took half doses.
The trial was conducted in accordance with principles of the Declaration of Helsinki, and
each study center was required to get the protocol, including the final version of the patient-
information and informed-consent form, approved by its ethics committee.
Endpoint ascertainments
Endoscopists counted the actual number of polyps in the rectum and sigmoid colon if there
were 10 or fewer and provided an estimate (11–15, 16–20, 21–30, 31–50, 51–100, >100)
when more numerous. We also collected data on the total number of polyps (rectum and
sigmoid, ascending, transverse, and descending colon), which presented a challenge because
of differing endoscopy policies and the challenge of the total number of polyps in an FAP
patient, which can run into the thousands. When the study was initiated, many centers used
sigmoidoscopy under sedation to monitor young people with FAP and usually avoided polyp
removal unless a polyp became very large or appeared to be advanced. Some centers relied
on paediatric endoscopists who tended to prefer full colonoscopy under anaesthetic. A
diagrammatic form was used to clarify polyp-count (actual or estimated) instructions and to
invite the endoscopist to mark the maximum extent of examination. The size of the largest
polyp was recorded on the form (estimated by comparing the polyp with open 5-mm biopsy
forceps).; We also requested all centers to record a withdrawal video of the rectum. If it was
necessary to remove polyps, we asked that a recording be made before and after the
removal. We specified rectal videos because we expected higher compliance among busy
endoscopists with a rectal versus a more-comprehensive, more-time–consuming video. At
least two withdrawal recordings in different perpendicular planes (i.e., at 90°) or with views
taken from 10, 2, and 6 o’clock and starting at 20 cm from the anal verge were requested. At
least twice during the recording, 5-mm forceps were opened near a polyp to assess the size
of polyps and to provide a scale for the views. Almost all endoscopists complied with the
request for open-forceps reference images, but there was considerable variation in extent of
recording, with some offering a full-withdrawal recording rather than only imaging the
rectum. The video recordings were scored (better, worse, or same) by two experienced
endoscopists (SB and RKSP) blinded to intervention and the time point of examination
(baseline, first year, second year, etcetera).
For assessing proliferative-state endpoints, six 5-mm mucosal biopsies were obtained from
macroscopically normal mucosa from 5 to 15 mm from the anal verge; two biopsies were
fixed in 75/25 absolute alcohol/glacial acetic acid for CCP, two were fixed in methacarn
fixative (60 methanol:30 chloroform:10 glacial acetic acid) for PCNA immunostaining, and
two in 10% neutral buffered formalin for determining Ki67 via MIB-1 immunostaining;
these samples were transported to Newcastle University for processing. On receipt, CCP
samples were transferred to 70% alcohol for long term storage.
Data and safety monitoring
Located in Newcastle University, the CAPP Operations Center housed the CAPP Principal
Investigator (JB), Study Manager, Research Associate/Recruiter, technician, and pharmacist
and coordinated the activities of the formal, independent CAPP Data Monitoring Committee
(DMC) and the CAPP Steering Committee, which comprised multidisciplinary members to
Burn et al. Page 4
Cancer Prev Res (Phila). Author manuscript; available in PMC 2011 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
help in guiding the trial. The Operations staff coordinated day-to-day administration of the
study, including dealing with study inquiries, distributing intervention packs, and collecting
surveillance data including the hand-marked colorectal forms (which recorded the number
and location of adenomatous polyps and size of the largest polyp in the examined colorectal
segments), video recordings, and biopsy material for storage and processing. The Operations
Center also offered study sites the option of genetic testing for the FAP-associated APC
mutation in samples obtained from prospective patients. All trial data were transmitted by
the study sites to the Operations Center, where they were entered into a computerized study
database and transmitted ultimately to the trial Statistical Center at Leeds University for
analysis; prior to the end of study, only randomization data were held at the CAPP Statistical
Center in Leeds. The CAPP Study Manager and principal investigator visited study sites
frequently on an ad hoc basis, conducting chart reviews and other procedures necessary to
ensure the integrity of the data and safety of patients. The CAPP statistical team at Leeds
University annually reported the trial data to the DMC, chaired by Professor Doug Altman
(London, Cancer Research UK), for safety and efficacy review. The DMC was responsible
for interrupting the trial if and when warranted by statistically significant preliminary
results. All of these operational procedures were facilitated by the long-standing
collaborative association of our sites as members of a trials consortium called the Leeds
Castle Polyposis Group, one of the two research communities which gave rise to the
International Society for Gastrointestinal Tumours (InSiGHT – www.insight-group.org)
Compliance
To maintain interest in study participation, recruitment-site personnel were asked to contact
each study patient at least once every six months to coincide with a delivery of study tablets
and sachets to the patient. Unused tablets and sachets were collected, counted, and recorded
by the recruiters to assess compliance with study interventions. The Operations Center sent
study tablets and sachets once a month to the study sites so as to maintain regular, monthly
contact with the sites; the Center also provided patients with regular updates of study
progress to maintain enthusiasm.
Laboratory methods
We assayed proliferative states via three techniques (21) so as to assure reliable results for
this important aberration. We used a) a crypt-microdissection method in tissue fixed in
alcohol/acetic acid to provide estimates of CCP because this method is technically robust
and b) two methods that applied antibodies to sections of formalin-fixed tissue for
identifying dividing cells marked by the antibodies against PCNA and Ki67. As described
earlier in Methods, six variously fixed biopsies were taken from normal mucosa near the
anal verge at the baseline and annual examinations. When required for histological analysis
to determine CCP, samples were re-hydrated, stained with Schiff’s reagent, and
microdissected to enable direct counts of total numbers (and location) of mitoses in whole
crypts (22). The numbers of mitotic cells in each tenth of the crypt by length were recorded;
crypt compartments were numbered from 1 (base) to 10 (luminal surface). Formalin-fixed
biopsies were paraffin-embedded and sectioned routinely prior to immunohistochemical
staining by MIB1 to detect Ki67 (22) and by PC10 to detect PCNA.
Crypt width and length were measured in the microdissected specimens and formalin-fixed
tissue sections via a graticule in the microscope eyepiece and were standardized via a
reference slide. Results from 10 crypts were averaged for each biopsy assessed.
Statistical methods
The study was designed to detect a statistically significant difference in the proportion of
patients with an increased polyp number in the rectum and sigmoid colon in the aspirin
Burn et al. Page 5
Cancer Prev Res (Phila). Author manuscript; available in PMC 2011 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
(versus the non-aspirin) group or in the RS (versus the non-RS) group at the end of
intervention (versus at baseline). The total number of polyps in the rectum and sigmoid
colon (prior to any polypectomy) at all endoscopies subsequent to baseline was the outcome
measure, i.e., the dependent variable using a random effects model. Data for the total
number of polyps seen in the rectum and sigmoid colon were available on all participants for
all colonoscopies.
We included the secondary endpoint of total number of polyps throughout the colon
(adjusted for the extent of endoscopy to account for the variable completeness of endoscopy)
so as to make more complete use of collected data. Variability in local policy over extent of
endoscopy meant that polyps were counted, or estimated when too dense, in differing
numbers of colorectal segments. We allowed for this variability by adjusting models for
extent at all endoscopies subsequent to baseline, including it as an independent variable in
the random effects models. Prior to the random effects modelling, linear regression was
performed so that total number of polyps at baseline endoscopy was the dependent variable
and extent at baseline endoscopy was the independent variable. Adjusted values were
calculated from the linear regression, i.e., we computed the difference between the observed
number of polyps at baseline and the average number of polyps for that extent at baseline
endoscopy. This adjusted number of polyps at baseline was then included in the random
effects model as an independent variable.
This was a 2 × 2 factorial analysis that compared the two aspirin arms combined (aspirin
plus RS and aspirin plus placebo) with the RS-plus-placebo and placebo-plus-placebo arms
combined, and compared the two RS arms combined (RS plus aspirin and RS plus placebo)
with the aspirin-plus-placebo and placebo-plus-placebo arms combined. We estimated an
event rate of 40% in non-responding patients, i.e., that 40% of the patients in that group
would have an increased polyp number (rectum, sigmoid colon) at the end of intervention,
and an intervention effect of 50% fewer patients (i.e., a total of 20%) developing an
increased number in the responsive intervention group, based on the average effect recorded
in the published observational studies (23). Due to the suggestion in some of these studies
that the effect was greater with prolonged use, the present study was designed to allow
participants to remain on study for as long as they could tolerate the interventions. The final
sample size estimate of 208 patients, 52 in each of the four arms of the factorial design, was
based on early data indicating that almost all patients had detectable pathology and was
designed to detect the anticipated intervention effect with an 80% power and alpha level of
0.025.
Major, prespecified secondary analyses included the size of the largest polyp at the end of
intervention and assessed in the subset of patients who remained on study for > 1 year; these
patients were anticipated to be more likely to be fully compliant and to respond to an active
intervention. Measurements of crypt length and width, hemicrypt cell count, and
proliferation in normal mucosal biopsies also were secondary endpoints; these endpoints
were considered exploratory since there were no prior data on potential effects on which to
base power calculations.
Eight outcome measures were analyzed: three clinical endpoints (number of rectal and
sigmoid polyps, largest polyp size [mm], and overall polyp number) and five exploratory
translational endpoints (mean total CCP, crypt width, crypt length, the mean number of
MIB1-positive cells per crypt, and the mean number of cells per hemicrypt). All but the last
variable were log transformed before analysis; for log-transformed outcome measures, the
exponent of the intervention coefficient was taken to indicate the ratio of the outcome
measure in treated to untreated patients; a ratio of 1.0 indicates no differences between
treated and untreated patients.
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Analysis of variance (ANOVA) and Pearson Chi-squared tests were carried out to compare
baseline measures. Associations between the baseline measures and age and sex were tested
using two-sided t-tests, Chi-squared tests, and Spearman’s correlations. Spearman’s
correlation coefficients were calculated for all pair-wise combinations of the continuous
baseline measures. Differences in final largest polyp size between the four intervention
groups were investigated using linear regression. Modeling involved estimation of random
effects, linear models, and generalized estimating equation (GEE) logit models to identify
main effects and possible interactions between intervention and time. The primary analyses
compared the two arms containing aspirin with the two arms not containing aspirin and
separately compared the two arms containing RS with the two arms not containing RS. The
outcome measures in these models comprised all results obtained after entry endoscopy, and
all models were adjusted for entry data and time on the intervention (years). In addition, the
random-effects models for the total number of polyps were adjusted for age and extent, i.e.,
the proportion of the colorectum examined. The total polyp number at entry was adjusted for
the extent of endoscopy via adjusted values from linear regression; in specific, we computed
the difference between the observed number of polyps and the average number of polyps for
that extent of endoscopy. This residual number formed the adjusted total of polyps at entry
endoscopy. In analyses of numbers of polyps, the number of polyps which were removed at
any endoscopy other than the last was added to the total number of polyps recorded at the
following endoscopy.
We tested differences between interventions in results from video analysis with Fisher’s
exact test. All analyses were carried out using STATA version 8 (StataCorp. 2003. Stata
Statistical Software: Release 8.0. College Station, TX: Stata Corporation), and probabilities
less than 0.05 were considered significant.
Results
Patient characteristics
Recruitment to this trial took place in 12 international centers from June 1993 until April
2002. Initially 227 young people with intact colons were recruited into the study and 206 of
these started the intervention (Fig. 1). Fifty-nine percent (133/227) had a baseline and at
least one other endoscopy and were therefore eligible for data analyses. At baseline, these
patients ranged in age from 10 to 21 years old, with a mean age of 18 years, and half were
female (Table 1). Patients were offered the option of leaving study at one year but were
invited to remain on study past one year, some remaining on intervention for up to 7 years
before the study ended. The study was approved by the relevant ethical committees in the
participating countries. All recruits provided informed consent for their participation in the
study and the provision of tissue samples.
Withdrawal rates in each intervention group were compatible with random loss [χ2 (3) =
5.0; P = 0.3]. For the 94 patients excluded from analysis, there was a non-significant
difference in age at “dropout” between the four intervention groups (ANOVA, P = 0.06). Of
the patients included in the final analysis, 57% (76/133) had two colonoscopies, 23%
(30/133) had three colonoscopies, 11% (15/133) had four, and 9% (12/133) had 5–8
colonoscopies. No polyps were found in 15% of the colonoscopies; 57% of the
colonoscopies went further than the sigmoid colon.
At baseline, the four intervention groups were well matched with regard to sex [χ2 (3) = 6.2,
P = 0.1], age (ANOVA, P = 0.90), or any of the polyp and crypt parameters shown in Table
1. Younger patients tended to have more polyps at study entry (data not shown). At entry
endoscopy, 41% of patients had one or more polyps removed; these patients tended to be
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older (mean age of 19 years) than those who did not have polyps removed (mean age of 16
years; two-sided t-test, P = 0.06).
Polyp assessments
After a median intervention period of 17 months (range 1 to 73 months), the risk of an
increased polyp number in the rectum and sigmoid colon (primary endpoint) was not
significantly reduced in either the aspirin or RS group (versus its counterpart group), with
relative risks of 0.77 (aspirin; 95% CI, 0.54–1.10; versus non-aspirin) and 1.05 (RS; 95%
CI, 0.73–1.49; versus non-RS group; Table 2). The diameter of the largest polyp (major
secondary endpoint) detected by the endoscopist at the end of intervention tended to be
smaller in the aspirin group (P = 0.05 and P = 0.09 after adjusting for baseline measures;
Table 3). The planned subgroup analyses of patients who elected to continue on study for
more than one year found a significant reduction in the size of the largest polyp in the
aspirin versus non-aspirin group (P = 0.02, adjusted for baseline; Table 3). We found an
absence of polyps in the majority of our blinded review of rectal videos (both at baseline and
during intervention), even though there were adenomas in the colon, so that most of the
annual rectal videos in the four intervention categories received the same score as did the
baseline video. The risk of an increased total number of polyps in all examined segments of
the colorectum (data not shown for this total number) was not reduced in either intervention
group, with relative risks of 0.97 (aspirin; 95% CI, 0.65–1.43; versus non-aspirin) and 0.96
(RS; 95% CI, 0.65–1.42; versus non-RS).
Crypt dimensions in macroscopically normal rectal mucosa
Relative risks of effects of intervention on crypt width and length are shown in Table 2.
Mean crypt length decreased significantly over time on study in the two combined RS
groups, compared with the two combined non-RS groups (P < 0.0001 for interaction), in a
model of the interaction between intervention and time (Fig. 2).
Proliferation-state assessments (CCP, Ki67, PCNA)
Histological examination of microdissected crypts from biopsies of apparently normal
mucosa indicated increases in total CCP of 28% (P = 0.12) in the RS versus non-RS group
and 37% (P = 0.05) in the aspirin versus non-aspirin group (Table 2). Ki67 results are also
indicated in Table 2 (“Number of MIB1-positive cells”). Although both the microdissection-
based method for CCP and the MIB1-staining method for Ki67 worked well during trial, the
PCNA-based method proved to be unsuitable for a dispersed multi-center study such as
CAPP1; the prolonged and variable immersion of samples in formalin due to differing
durations of transport made PCNA recovery very problematical; and the PCNA results were
considered to be too unreliable for analysis.
Toxicity
No serious adverse effects were recorded. Some bloating was reported among RS takers.
One participant in the aspirin/RS arm withdrew because of persistent nose bleeds. There
were no other reports of bleeding or of cardiovascular or cerebrovascular events. The most
common reason cited for withdrawal from study was difficulty in including starch in the
habitual diet. There was no statistically significant difference between starch and its
matching placebo or aspirin and its matching placebo in rates of withdrawal.
Discussion
This trial of aspirin (600 mg/d) and RS (30 g/d) in preventing adenoma occurrence in young
people (mean age 18 years) with FAP is the largest clinical trial ever conducted in this
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setting. There was a non-significant trend of a reduced number of polyps in the rectum and
sigmoid colon (primary endpoint) in the overall aspirin group (aspirin plus placebo and
aspirin plus RS) versus the non-aspirin group at the end of intervention (Table 2). There also
was evidence that the size of the largest polyp (secondary endpoint) was reduced in the
overall aspirin versus the overall non-aspirin group (Table 3). Furthermore, among those
treated for more than one year, the diameter of the largest polyp recorded in the aspirin
group (3.0 mm) was only half that recorded in the non-aspirin group (6.0 mm; P = 0.02).
Results of RS are discussed later.
Previous randomized trials (3-6,) support the view that long-term (1–3 years) aspirin
ingestion (81 mg/d–325 mg/d) results in a small but significant reduction in colonic
adenoma formation in older persons with previous sporadic adenomatous polyps or CRC. In
contrast, the CAPP2 Study (which used interventions similar to those in the present CAPP1
Study) revealed no apparent beneficial impact on colorectal neoplasia (largely adenomatous
polyps) of either aspirin at 600 mg or RS at 30 g daily in people with Lynch syndrome
(hereditary nonpolyposis colorectal cancer [HNPCC]) after intervention for 29 months (24).
Subsequent follow-up of participants in the CAPP2 Study suggests an impact on subsequent
cancers despite the lack of effect on adenoma formation (25). The modest efficacy of aspirin
in intervention studies reported to date contrasts with the very substantial evidence from
observational epidemiological studies showing an approximately 50% reduction in risk of
CRC among regular aspirin takers over prolonged periods (26). These data suggest that
aspirin may inhibit cancer in ways other than through inhibiting adenoma growth and
development.
Several studies since the CAPP1 study was initiated lend support to the chosen
interventions; the large cohort study European Prospective Investigation into Cancer and
Nutrition (EPIC) (27, 28) demonstrated a lower CRC risk in people with a higher dietary
fiber intake. It is probable that a higher fiber intake is associated with a higher intake of RS.
The NSAID celecoxib has been shown to inhibit adenoma development in patients with
previous adenomas (29, 30), although concurrent low-dose aspirin use had no additional
impact. A study involving one of our senior authors (RKSP) drew on early experience from
CAPP1 and demonstrated an inhibitory effect of celecoxib on adenoma development in FAP
(31). One of the potential limitations of the CAPP1 Study was that data on polyp numbers
and sizes were collected by multiple endoscopists at several centers during a period of
substantial improvements in endoscopy performance. These issues likely increased the
variation in estimates of polyp burden and so reduced the ability to detect effects of the
interventions. The Steinbach et al. study (31) avoided these problems by using only two
specialist endoscopy teams.
Assuming that more-compliant patients would volunteer to remain on study after the first
planned exit opportunity (at one year), we planned secondary analyses of patients who
remained on study for more than one year. These analyses revealed a significantly beneficial
effect of aspirin on polyp size (Table 3). The impact of aspirin in reducing the recorded size
of the largest polyp is a finding of potential clinical importance since it would imply an
effect on disease progression rather than initiation. There has been considerable focus on
cyclooxygenase 2 (COX-2) inhibition as a mechanism for colorectal cancer prevention, but
the COX inhibitory properties of aspirin are largely against COX-1. Aspirin has effects on
other pathways of importance in tumorigenesis, however; for example, Stark et al. (32)
showed that aspirin suppresses nuclear factor kappa B (NFκ-B)-driven transcription and
enhances apoptosis. We have demonstrated in vitro inhibition of new blood-vessel formation
by physiological concentrations of salicylate (33). Such effects might prevent small
adenomas from progressing to malignancy; even a modest reduction in the volume of large
polyps will reduce the number of cells exposed to subsequent genetic alterations leading to
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malignant transformation. The evidence of an aspirin impact on the progression of neoplasia
is in keeping with protective effects against colon cancer more than a decade after aspirin
therapy stopped in cardiovascular prevention trials of the 1980s; these findings were
extended by recent analyses of cardiovascular trials of low-dose aspirin that revealed a
similar, but smaller, delayed effect on colorectal cancer incidence and cancer death (34) .
There was no detectable effect of RS on number of polyps in the rectum and sigmoid colon
in the primary analysis. Secondary findings indicated that longer-term use of RS was
associated with a significant reduction in crypt length in normal-appearing mucosa. This
discovery is of biological interest and may provide an independent indicator of compliance
with the intervention. There was no evidence that RS supplementation had any adverse
effect on adenoma risk. Epidemiological studies suggest that higher starch diets (richer in
RS) are associated with reduced CRC risk, and there is strong evidence for antineoplastic
effects of butyrate, a major short-chain fatty acid produced in the colon from bacterial
degradation of RS. There have been reports, however, of increased neoplastic risk in rodents
given very large RS doses (much greater than those used in human studies; ref. 17).
Although we assessed both aspirin and RS for effects on the total number of polyps in all
examined segments of the colorectum, multicenter and international variability in the extent
of colon examined beyond the sigmoid segment made results of these analyses highly
variable and difficult to interpret despite our rigorous efforts to account for this variability.
The CAPP1 Study in isolation does not provide sufficient evidence to recommend long-term
use of aspirin in FAP patients. It might be argued, however, that seen in the light of recent
publications suggesting a long term benefit in cancer prevention (34), aspirin is worthy of
further evaluation in FAP patients who retain segments of the colorectum, particularly in the
context of concern over the potential side effects of selective COX-2 inhibitors.
Although aspirin and RS had limited (or no) demonstrable effect in CAPP1 on polyp
formation in FAP, it remains to be established whether these agents are effective in other
settings. The CAPP2 Study tested the effect of similar interventions in an older, genetically
susceptible population with pathological mutations in mismatch repair genes (Lynch
syndrome or HNPCC). After 29 months of intervention, there was no significant effect of
either intervention agent on colorectal neoplasia (largely adenomatous polyps). Recent
results from long-term follow-up, however, suggest effects on carcinoma occurrence after
cessation of the intervention. These results are consistent with the conclusion that the anti-
neoplastic effects of aspirin intervention may take many years to appear.
The CAPP1 study successfully recruited and retained 113 participants with FAP, but many
challenges have made this low-cost international approach based on FAP registries less
attractive than was originally hoped. These challenges include the young age of the group
under investigation; variable clinical practices in different countries meaning that
colonoscopies were highly variable in terms of the extent of colonic investigation; and
successful follow-up when working with so many different clinical groups, each of which
could recruit only limited numbers of participants because of the low prevalence of the
disease. Nevertheless, the genetically susceptible population must remain of primary interest
given their capacity to provide a model system for disease processes usually too lengthy to
be studied in the prevention setting.
Footnotes
Corresponding Author: Prof. Sir John Burn MD Institute of Human Genetics, Newcastle University, Centre for
Life Newcastle upon Tyne NE1 3BZ Phone: +44 191 241 8734; Fax: [+44 191 241 8666]; john.burn@ncl.ac.uk.
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15Investigators participating in CAPP1 are listed in the Appendix. CAPP originally stood for Concerted Action
Polyp Prevention of the European Union and now stands for Colorectal Adenoma/Carcinoma Prevention
Programme.
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Fig. 1.
CAPP1 consort diagram.
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Fig. 2.
Mean length of microdissected crypts over time on study in patients of the resistant starch
(RS) group (RS plus aspirin placebo, RS plus aspirin) or of the non-RS group (aspirin plus
RS placebo, aspirin placebo plus RS placebo). Crypts tended to lengthen with time on study
for the non-RS group, whereas they shortened in the RS group (P-value for interaction <
0.0001).
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